The consoritum had a zoom meeting on the 05.06.2021 with more than 40 participants for a full day of training…
A european consortium with research teams from 10 different european sites, to develop clinical trials in order to prevent or delay Alzheimer’s disease in the population with Down syndrome.
The Horizon 21 Consortium was born from a collaboration between clinicians from various european centers offering a consultation dedicated to adults and seniors with Down syndrome.
This program aims at identifying the factors that influence the development of Alzheimer’s disease in persons with Down syndrome. The consortium wants also to develop cognitive assesment tools and biomarkers which could be relevant for clinical trials. Of course, the main objective is to prevent and/or delay the onset of Alzheimer’s disease in this specific population.
Large-scale genotyping of persons with Down syndrome in order to identify risk or protective factors of Alzheimer's disease.
Harmonisation of cognitive evaluation tools
e.g neurofilaments light analysis in plasma.
Impact of Alzheimer’s disease on sleep of adults with Down syndrome.
We are very pleased to welcome you on our new website. You will find on this website all the informations relative to the Horizon 21 consortium.